REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

China Sxt Pharmaceuticals Inc. (China)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: China Sxt Pharmaceuticals Inc. Profile Updated: February 03, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English & Chinese Download a sample report

China SXT Pharmaceuticals, Inc is a pharmaceutical company. They claim to have received government funding and are currently producing a variety of modern Pharmaceutical Drink Pills, refined Pharmacological Drinks, and ordinary Pharmakological drinks.

Headquarters
178 Taidong Rd North
Taizhou; Zhejiang; Postal Code: 225300

Contact Details: Purchase the China Sxt Pharmaceuticals Inc. report to view the information.

Website: http://www.sxtchina.com

Basic Information
Total Employees:
Purchase the China Sxt Pharmaceuticals Inc. report to view the information.
Outstanding Shares:
Purchase the China Sxt Pharmaceuticals Inc. report to view the information.
Financial Auditors:
Purchase the China Sxt Pharmaceuticals Inc. report to view the information.
Incorporation Date:
March 04, 2026
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Chief Executive Officer
Purchase this report to view the information.
Chief Financial Officer
Purchase this report to view the information.
Director/Member of the Board
Purchase this report to view the information.
Director/Member of the Board
Ownership Details
Purchase this report to view the information.
Subsidiaries
China Sxt Group Limited (Hong Kong SAR, China)
Jiangsu Su Xuan Tang Pharmaceutical Co. Ltd.
Taizhou Su Xuan Tang Biotechnology, Co. Ltd.
Company Performance
Financial values in the chart are available after China Sxt Pharmaceuticals Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
-24.24%▼
Total operating revenue
-24.24%▼
Operating Profit/Loss (EBIT)
-922.38%▼
EBITDA
-1014.03%▼
Net Profit/Loss for the Period
-694.53%▼
Total Assets
-13.79%▼
Total Equity
36.46%▲
Operating Profit Margin (ROS)
-935.93%▼
Net Profit Margin
-918.93%▼
Return on Equity (ROE)
-26.14%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo